Insider sale details
Immunovant, Inc. NASDAQ:IMVT confirmed that its Chief Technology Officer, Jay S. Stout, sold 10,132 shares of common stock on April 8, 2026, for approximately $251,577. The trades were executed at a weighted average price of $24.83, within a reported range of $24.54 to $25.39. Market quotes at the time placed the shares near $24.50.
Reason for the sale
The transactions disclosed on the Form 4 were carried out to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units (RSUs). Following the sale, Stout directly holds 254,439 shares of Immunovant stock.
Valuation context
InvestingPro analysis referenced alongside the filing indicates that Immunovant is trading above its Fair Value and is listed among companies deemed Most Overvalued. The company is described in the filing as a roughly $5 billion biotech, which has delivered a 73% return over the trailing 12 months.
Additional research offering
For readers seeking more detail on valuation and insider activity, the filing notes that a full Pro Research Report is available exclusively on InvestingPro and that it includes six additional ProTips and comprehensive analysis.
Clinical update: batoclimab Phase 3 results
In recent company disclosures, Immunovant announced that its Phase 3 clinical trials of batoclimab for thyroid eye disease did not meet the pre-specified primary endpoint. The trials involved adults with active, moderate-to-severe thyroid eye disease and failed to achieve a statistically significant proptosis response at Week 24.
Analyst response and pipeline emphasis
Brokerage firms have adjusted their views and price targets in response to the clinical outcome while also weighing the company’s broader pipeline. Truist Securities reiterated a Hold rating with a $23.00 price target. Leerink Partners reduced its price target to $50 from $52 but kept an Outperform rating. Oppenheimer maintained an Outperform rating and a $54.00 price target, citing the potential of the next-generation FcRn program IMVT-1402 in alternate indications. Separately, Bernstein SocGen Group initiated coverage with a Market Perform rating and a $28.00 price target, and valued Immunovant’s Graves’ disease and Sjogren’s syndrome programs at $2.4 billion and $2.0 billion respectively on a non-risk-adjusted basis.
Takeaway
These recent developments reflect a mix of cautious optimism about longer-term pipeline candidates and immediate challenges tied to a failed primary endpoint for batoclimab. The insider sale reported by the CTO was tax-driven per the Form 4 disclosure and follows a year in which the stock has posted substantial gains.
Data points
- Insider: Jay S. Stout, Chief Technology Officer
- Shares sold: 10,132 on April 8, 2026
- Proceeds: approximately $251,577
- Weighted average sale price: $24.83 (range $24.54 to $25.39)
- Shares owned after sale: 254,439
- Company market reference: about $5 billion; 73% return over past year
- Clinical: Batoclimab Phase 3 did not meet primary proptosis endpoint at Week 24
- Analyst actions: Truist - Hold $23.00 PT; Leerink - Outperform $50 PT (from $52); Oppenheimer - Outperform $54.00 PT; Bernstein SocGen - Market Perform $28.00 PT